Alexandria Real Estate stock holds steady as investors await catalysts.

Alexandria Real Estate stock centers on its life science real estate portfolio and long-term biotech tenant base.

Alexandria Real Estate Equities, Inc. (ISIN US0152711022) is a major life science real estate landlord listed on the NYSE under the ticker ARE.

Business model

The company owns and develops properties designed for laboratory and office use, with demand tied to biotechnology, pharmaceutical, and research tenants. That makes the stock more exposed to life science leasing trends than to broad office real estate sentiment.

Market context

For US investors, Alexandria sits in a distinct REIT niche rather than the general office segment, which is the key analytical difference for the shares. The company has also been a familiar name in institutional portfolios because of its concentration in innovation clusters.

Representative property type

Alexandria's core product is specialized lab and office space for life science tenants, including campus-style properties in major research markets. That real estate mix is the defining operating lever for revenue growth and occupancy trends.

Shares and listing

Alexandria Real Estate Equities, Inc. trades on the New York Stock Exchange as ARE. As of July 16, 2026, no verified live price is available in this article.

Fact box

• Company: Alexandria Real Estate Equities, Inc.
• ISIN: US0152711022
• Ticker: ARE
• Exchange: NYSE
• Sector / Industry: Real Estate / Office REIT